Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Venous thromboembolism is a serious complication after total hip replacement (THR) and total
knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and
symptomatic deep vein thrombosis (DVT) after TKR were higher in Taiwan than other countries
in Asia. Therefore, the usage of prophylactic antithrombotics should be considered. The
efficacy and safety of Xarelto (Rivaroxaban) for preventing venous thromboembolism has been
proved. However, there is a lack of study using prospective design to evaluate the efficacy
and safety of Xarelto after THR and TKR for Taiwanese. In this study, we use a randomized
controlled trial design comparing the incidence of DVT, pulmonary embolism, and complications
between intervention and control groups.